


# ***ENDOVASCULAR AORTIC REPAIR***



***Kay-Hyun Park***

*Department of Thoracic and Cardiovascular Surgery*

*Seoul National University Bundang Hospital*



*“Many cardiovascular surgeons are looking at the achievement of TEVAR with a bitter-jealous admiration. Some pessimists tend to think that shrewd cardiologists and radiologists will overtake surgeons in treating aortic aneurysms.”*

*- Yutaka Okita, 2007 -*

# *Endangered Species ??*



Squirrel



Bighorn Sheep



Lemur



Aorta surgeon



Mongoose



Panda



Manatee



Wallaby



Otter



Camel



Gray Wolf




Bat

# Transfemoral Intraluminal Graft Implantation for Abdominal Aortic Aneurysms

J.C. Parodi, MD\*, J.C. Palmaz, MD<sup>†</sup>, H.D. Barone, PhD, *Buenos Aires,  
Argentina, and San Antonio, Texas*

(Ann Vasc Surg 1991;5:491-499)



- Experiments since 1976
- First clinical application in 1990
- Report of 5 cases
  - 3 success
  - 1 endoleak
  - 1 conversion to open surgery



# The New England Journal of Medicine

©Copyright, 1994, by the Massachusetts Medical Society


Volume 331

DECEMBER 29, 1994

Number 26

## **TRANSLUMINAL PLACEMENT OF ENDOVASCULAR STENT-GRAFTS FOR THE TREATMENT OF DESCENDING THORACIC AORTIC ANEURYSMS**

MICHAEL D. DAKE, M.D., D. CRAIG MILLER, M.D., CHARLES P. SEMBA, M.D., R. SCOTT MITCHELL, M.D.,  
PHILIP J. WALKER, M.B., B.S., AND ROBERT P. LIDDELL, B.A.




- First clinical application in 1992
- 13 patients

➤ Animal study since 1984

➤ Clinical use since 1985



***Nikolai L. Volodos***

В  СОЮЗ СОВЕТСКИХ  
СОЦИАЛИСТИЧЕСКИХ  
РЕСПУБЛИК

(SU) SU (SU) 1217402 A


Ω 4 А 61 F 2/06

ГОСУДАРСТВЕННЫЙ КОМИТЕТ СССР  
ПО ДЕЛАМ ИЗОБРЕТЕНИЙ И ОТКРЫТИЙ

**ОПИСАНИЕ ИЗОБРЕТЕНИЯ**  
**К АВТОРСКОМУ СВИДЕТЕЛЬСТВУ**


(21) 3744158/28-14  
(22) 22.05.84  
(46) 15.03.86. Бюл. № 10  
(71) Харьковский научно-исследовательский институт общей и неотложной хирургии и Харьковский ордена Ленина, ордена Октябрьской Революции и ордена Трудового Красного Знамени моторостроительный завод «Серп и Молот»  
(72) Н. Л. Володос, В. Е. Шеханин и И. П. Карлович  
(53) 615.475 (088.8)  
(56) Авторское свидетельство СССР № 660689, кл. А 61 М 29/00, 1977.

(54) (57) ПРОТЕЗ КРОВЕНОСНОГО СОСУДА, состоящий из эластичной оболочки с фиксирующим элементом, отличающийся тем, что, с целью упрочнения установки протеза и увеличения надежности фиксации, фиксирующий элемент выполнен в виде плоской изогнутой пружины, вершины изгибов которой имеют петлеобразную форму и закреплены на внутренней стенке протеза.



№ SU (SU) 1217402 A

# Endovascular zone




# Case selection - feasibility



- 고정할 곳이 있는가?
- 적당한 크기의 *stent graft*가 있는가?
- *Stent graft*를 *target*까지 집어 넣을 수 있는가?
- *Contrast agent*를 사용할 수 있는가?
- **Landing zones – proximal & distal**
  - Length : **≥ 2cm**, *the longer the better*
  - Diameter
- Access vessel size & tortuosity
- Renal function
- Contrast allergy






# Proximal Landing Zone



# Good vs. poor proximal neck

---





#### Product Code

	Proximal Graft Diameter (mm)				
	Distal Graft Diameter (mm)				
VAMF	22	22	C	100	TE
VAMF	24	24	C	100	TE
VAMF	26	26	C	100	TE
VAMF	28	28	C	100	TE
VAMF	32	32	C	200	TE
VAMF	34	34	C	200	TE
VAMF	36	36	C	200	TE
VAMF	38	38	C	200	TE
VAMF	40	40	C	200	TE
VAMF	42	42	C	200	TE
VAMF	44	44	C	200	TE
VAMF	46	46	C	200	TE

#### Graft Covered Length (mm)<sup>1</sup>

#### Total Stent Graft Length (mm)

#### Catheter Outer Diameter (F)

112	124	22
112	124	22
112	124	22
112	124	22
192	204	22
212	224	24
207	219	24
207	219	24
212	224	24
207	219	25
212	224	25
212	224	25

# Difficult access

---

small vessel



tortuosity



occlusive disease






# Case selection - feasibility




- 고정할 곳이 있는가?
- 적당한 크기의 *stent graft*가 있는가?
- *Stent graft*를 *target*까지 집어 넣을 수 있는가?
- *Contrast agent*를 사용할 수 있는가?
  
- **Landing zones – proximal & distal**
  - Length
  - Diameter
  - Access vessel
  - Aortic tortuosity
  - Renal function
  - Contrast allergy

# Suitability of EVAR




# Hostile or marginal anatomy

---



# Case planning

- **Which device?**
- **Size (diameter)**
  - oversizing 15~20%  
(around 10% for dissection)
- **Length**
  - extent of coverage
- **Number of device**
  - single or  
multiple with overlap
- **Which route?**






# Thoracic Endovascular Aortic Repair



**Cook TX2**



**Gore TAG**



**S&G Seal**

**Medtronic  
Captivia**



## Valiant® Thoracic Stent Graft System

FREEFLO STRAIGHT  
(PROXIMAL COMPONENT)  
VAMF (22-46 mm)



CLOSED WEB STRAIGHT  
(DISTAL COMPONENT)  
VAMC (22-46 mm)




CLOSED WEB TAPERED  
(DISTAL COMPONENT)  
VAMC (22-46 mm)  
Tapered End (22-42 mm)



DISTAL BARE SPRING STRAIGHT  
(DISTAL COMPONENT)  
VAMC (22-46 mm)



# Procedure



- Imaging  
--- fluoroscopy, screen, table
- Puncture kit
- Guidewire
- Catheter
- Sheath
- Dilator
- Balloon
- stent

# Qualifications for credentialing of cardiothoracic surgeons to perform endovascular stent-grafting of the thoracic aorta

*- STS / AATS Position Statement, 2006 -*

## **Knowledge**

*broad understanding  
of disease entity*

## **Technical expertise**



*all therapeutic options  
(conventional & new)*

## **Training**



*specific to endo-  
vascular approach*

- Experience with 10 open surgical procedures
- Minimum of 25 wire/catheter placements
- Participation in 10 abdominal or 5 thoracic aortic EVSG
- Experience with large-bore femoral sheath cannulation
- Experience with retroperitoneal exposure of the iliac arteries






# Chimney technique




# Hybrid TEVAR with arch debranching

---




# Zone 0 option

Type I



Type II



Type III



# Elephant Trunk + TEVAR

- Conventional total arch replacement with Elephant Trunk
- Second stage TEVAR instead of DTA replacement surgery



Pre-ope




1st ope




2nd ope






# Hybrid repair of thoracoabdominal aneurysm



# Fenestrated stent graft



# Branch stent graft



# Questions to be answered


- **Is endovascular repair**
  - able to treat all lesions?
  - safer than open repair for all patients?
  - as durable as open repair?
  - equally available as open repair?
  - less costly than open repair?

# Indication of endovascular repair in thoracic aorta : **established**

---


- thoracic aneurysm with good landing zones
  - ‘neck’ length  $\geq 2\text{cm}$ , ideally  $\geq 4\sim 5\text{cm}$
  - +/- sacrifice of left subclavian/ceeliac a.
- traumatic (isthmic) rupture
- post-surgical anastomotic pseudoaneurysm
- penetrating atherosclerotic ulcer
  - with IMH, false aneurysm, or pain
- complicated acute type B dissection






# Hostile or marginal anatomy

---



# Annual number of AAA treated in Korea


*Data from HIRA*




# How many AAA can be treated with EVAR?

## Endovascular Repair of Small Abdominal Aortic Aneurysms: A Paradigm Shift?

M. Burrell Welborn III, MD,\* Franklin S. Yau, MD,\* J. Gregory Modrall, MD,\*  
Jorge A. Lopez, MD,† Stephen Floyd, BSRT,† R. James Valentine, MD,\*  
and G. Patrick Clagett, MD,\* Dallas, TX




- 62-year-old female with fall-down injury → multiple fractures







- 58-year-old female with previous DTA replacement 14 YA



# Penetrating atherosclerotic ulcer (PAU)



- 54-year-old male
- Acute type B dissection with intractable pain




# TEVAR in type B dissection

---


complicated acute dissection

exclusion of  
intimal tear



*false lumen thrombosis*  
- - -> *regression*



*rupture*



*malperfusion*



# Indication of endovascular repair in thoracic aorta : **controversial or undetermined**


---

- retrograde type A dissection  
(primary tear in the descending aorta)
- infectious/mycotic aneurysm
- uncomplicated acute type B dissection
- chronic type B dissection
- inadequate landing zones necessitating
  - ‘debranching/rerouting’ procedures
  - adjunct procedures, e.g., chimney
  - new generation devices (fenestrated, branched)



# Rationale of TEVAR in **uncomplicated** dissection

---




# However, the reality is that

*Most dissections have distal re-entry tears, especially in chronic stage.*

**TEVAR**

≤ 80% in acute  
≤ 50% in chronic



Expert Consensus (report from STS task force) :

*“Neither open surgery nor stent-graft reverses the natural history of aortic dissection unless the entire extent of dissection is either resected or excluded, and that can be achieved only by surgical intervention”*

*courtesy of Taek Yeon Lee, MD*


- **F / 56, Marfan**
- **s/p TEVAR for type B dissection**



December 2009



June 2011



November 2011

# EVAR trial

*Lancet 2004;364:843-8*

- Randomization of elective AAA patients fit for open surgery
  - endovascular stent-grafting (n=543) vs. open surgery (n=539)

---

	EVAR	open repair
• median length of operation :	180min	200min
• 30-day mortality :	1.7%	4.7%
• median length of admission :	7 days	12 days
• conversion to open repair	1.8%	-----
• correction of endoleak	3.3%	-----
• re-exploration	-----	2.8%

---

# 1<sup>st</sup>-generation stent-grafts in thoracic aorta

---

*Demers P, Craig Miller D, et al. J Thorac Cardiovasc Surg 2004;127:664-73*

- 103 patients between 1992~1997, mean follow-up for 4.5 years
  - 62 patients were ‘*unsuitable for conventional open repair*’.
- mortality : 9%, paraplegia : 3%
- actuarial freedom from treatment failure : 67%/1-year, 56%/5-year

## Stent-grafting of thoracic aorta in France

---

*Ricco JB, et al. J Thorac Cardiovasc Surg 2006;131:131-7*

- Nationwide result of 166 patients in France between 1999 ~ 2001
- in-hospital mortality : 10%
- 49 complications in 34 patients (20.5%)
  - *endoleak : 16.3%, other serious complications : 12.7%*



# Secondary procedures after TEVAR

---

- **Talent registry** (*J Thorac Cardiovasc Surg* 2006;132:332-9)
  - 457 patients, 2<sup>nd</sup> procedure = 19% / 3 years, 30% / 5 years
- **Heidelberg** (*J Vasc Surg* 2011)
  - 47 patients of hybrid TEVAR (1997~2009)
  - 27.6% 2<sup>nd</sup> procedure, 6.3% open conversion
- **U Penn** (*J Thorac Cardiovasc Surg* 2013;145:S165-70)
  - 680 TEVAR (2000~2011) → 60 2<sup>nd</sup> TEVAR + 20 surgery
- **Kobe** (*Ann Thorac Surg* 2013;95:1584-90)
  - 147 TEVAR (2000~2011) → 10 2<sup>nd</sup> TEVAR + 9 surgery

# Systematic review of clinical outcomes in hybrid procedures for aortic arch dissections and other arch diseases

Piergiorgio Cao, MD, FRCS,<sup>a</sup> Paola De Rango, MD, PhD,<sup>b</sup> Martin Czerny, MD,<sup>c</sup> Arturo Evangelista, MD,<sup>d</sup> Rossella Fattori, MD,<sup>e</sup> Christoph Nienaber, MD,<sup>f</sup> Hervè Rousseau, MD,<sup>g</sup> and Marc Schepens, MD<sup>h</sup>

*J Thorac Cardiovasc Surg* 2012;144:1286-1300

## ➤ Conclusion

- Hybrid arch repair present a persistent high risk of mortality and neurologic morbidity, comparable with open repair.
- Mortality was not affected by center volume or time of experience.
- Zone 0 deployment present 3 times higher mortality than zone 1 repair.
- No reliable long-term data exist to ascertain the durability.

# *Endovascular repair of thoracoabdominal aneurysms: design options, device construct, patient selection and complications*

L. M. REILLY, T. A. M. CHUTER

*J Cardiovasc Surg* 2009;50:447-60

- Total number of pooled cases 287
- Follow-up < 18 months
  
- Early mortality **6.9%**
- Late mortality 13.6%
  
- Spinal cord ischemia
  - paraplegia **8.2%**
  - paraparesis 6.7%
  - permanent **6.7%**
  - temporary 10.0%

- Renal failure 9.8%
- Hemodialysis **5.1%**
  
- Early re-intervention 8.9%
- Late re-intervention **11.1%**
  
- Early endoleak 16.2%
- Late endoleak 14.3%
- Branch occlusion 3.5%

# Problems/complications of TEVAR

---

◆ Mortality	1.5~6.5%
◆ Renal failure	5.2~13%
◆ Vascular access problems	
➤ need of iliac conduit	up to 40%
➤ serious injury to iliofemoral arteries	1.4~14%
◆ Neurological complications	
➤ stroke	2.9~11%
➤ paraplegia	2~5%
◆ Procedural failure	1~5%
◆ Retrograde type A dissection	2~6%
◆ Endoleak	0~45%
◆ Late mechanical failure (fracture/breakage/wear)	up to 9%
◆ Prosthesis infection	???

## *Shaggy aorta – risk factor for both open repair and TEVAR*



---









# Endoleak - type I



# Endoleak - type II




*Intercostal artery*




*Lumbar artery*  
*Inferior mesenteric artery*  
*Median sacral artery*

# Endoleak - type III



# Endoleak - type IV (endotension)






# Post-TEVAR complications

---

*residual aneurysm*






*new adjacent aneurysm*



*distal erosion -aneurysm*


# Post-TEVAR complications



*aorto-esophageal fistula*



*stent-graft migration & false aneurysm*



# Mechanisms of Failure and Outcome of Secondary Surgical Interventions After Thoracic Endovascular Aortic Repair (TEVAR)

Julia Dumfarth, MD, Marc Michel, MD, Jürg Schmidli, MD, Gottfried Sodeck, MD, Marek Ehrlich, MD, Michael Grimm, MD, Thierry Carrel, MD, and Martin Czerny, MD

Departments of Cardiac Surgery, and Emergency Medicine, Medical University of Vienna, Vienna, Austria; Department of Cardiovascular Surgery, University Hospital Berne, Switzerland; and Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria

*Background.* We evaluated mechanisms of failure and outcome of secondary surgical interventions after thoracic endovascular aortic repair (TEVAR) for aortic aneurysm formation as well as infection. Retrospectively, by analysing referral computed tomography scans and by current knowledge, failure could have been foreseen in 72% of patients. Median interval to secondary surgical intervention was 24 months (IQR 8-40). Sixteen patients underwent thoracic or thoracoabdominal repair and five patients underwent thoracic or thoracoabdominal replacement. Further critical evaluation and respecting limitations of TEVAR will help to reduce the need for these operations.

(Ann Thorac Surg 2011;91:1141–6)  
© 2011 by The Society of Thoracic Surgeons



# Lessons

- 2<sup>nd</sup> procedure is not rare after TEVAR,  $\geq 20\%$  of them should be open surgery.

- *Causative factors for early failure*

- *off-label use for unfavorable anatomy*
    - *wrong indication, e.g., Marfan, infection*
    - *inadequate landing zone*

- Procedural / early success

≠ clinical / long-lasting stabilization

*because of late endoleak, adjacent aneurysm, infection, erosion (fistula), etc.*

- The best countermeasure to complication is prevention. Best outcome can be achieved by selecting appropriate procedures to appropriate patients.

It is why we need a real '*bivascular*' team that is good at both open surgery and endovascular procedure.



# Questions to be answered

- **Is endovascular repair**

- safer than open repair for all patients?

*mostly but not always*

- as durable as open repair?

*questionable*

- able to treat all lesions?

*maybe in the future, not in my life*

- equally available as open repair?

*doubtful, probably not*

- less or more costly than open repair?

*Newer devices will be too expensive for wide use*



“..... it is not prudent to offer endovascular stent graft repair to younger patients who do not have major contraindications to open surgical repair.....careful selection is key with particular emphasis on favorable anatomic targets.....”

*- Demers P, Craig Miller D, et al. JTCS 2004;127:664-73 -*



“The gold standard for treatment of the standard patient still is the conventional open procedure in the hands of excellence. Unfit for surgery is a term steeply increasing in the literature and sometimes seems to be occupied as license to stent in cases that could easily be handled in a specialized surgical centers” – *Sunder-Plassmann L. J Cardiovasc Surg 2005;46:121-30 -*

# complement *rather than* competition

